Reaction Details |
| Report a problem with these data |
Target | Mu-type opioid receptor |
---|
Ligand | BDBM86493 |
---|
Substrate/Competitor | n/a |
---|
Ki | 2.39±n/a nM |
---|
Comments | PDSP_2945 |
---|
Citation | Valenzano, KJ; Miller, W; Chen, Z; Shan, S; Crumley, G; Victory, SF; Davies, E; Huang, JC; Allie, N; Nolan, SJ; Rotshteyn, Y; Kyle, DJ; Broglé, K DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties. J Pharmacol Exp Ther310:783-92 (2004) [PubMed] Article |
---|
More Info.: | Get all data from this article |
---|
|
Mu-type opioid receptor |
---|
Name: | Mu-type opioid receptor |
Synonyms: | M-OR-1 | MOP | MOR-1 | MOR1 | MUOR1 | Mu Opioid Receptor | Mu opiate receptor | OPIATE Mu | OPRM1 | OPRM_HUMAN | hMOP | mu-type opioid receptor isoform MOR-1 |
Type: | G Protein-Coupled Receptor (GPCR) |
Mol. Mass.: | 44789.51 |
Organism: | Homo sapiens (Human) |
Description: | P35372 |
Residue: | 400 |
Sequence: | MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRTDLGGRDSLCP
PTGSPSMITAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALAT
STLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF
RTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTWYWENLLKICVFI
FAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHI
YVIIKALVTIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENFKRCFREFCIPTSSNI
EQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETAPLP
|
|
|
BDBM86493 |
---|
n/a |
---|
Name | BDBM86493 |
Synonyms: | CAS_27943 | NALTREXONE-HCl | NSC_27943 | Naltrexone |
Type | Small organic molecule |
Emp. Form. | C20H23NO4 |
Mol. Mass. | 341.4009 |
SMILES | Oc1ccc2CC3N(CC4CC4)CCC45C(Oc1c24)C(=O)CCC35O |TLB:22:23:7.12.13:5.4.18,THB:24:23:7.12.13:5.4.18| |
Structure |
|